2016 updated EULAR evidence-based recommendations for the management of gout

Annals of the Rheumatic Diseases

Volumn 76, Issue 1, 2017, Pages 29-42

  Richette, P ^a,r,s   Doherty, M ^b   Pascual, E ^c   Barskova, V ^d   Becce, F ^e   Castaneda Sanabria J ^f,s,t,u   Coyfish, M ^g   Guillo, S ^f,s,t,u   Jansen, T L ^h   Janssens, H ^h   Liote F ^a   Mallen, C ⁱ   Nuki, G ^j   Perez Ruiz, F ^k   Pimentao, J ^l   Punzi, L ^m   Pywell, T ^g   So, A ⁿ   Tausche, A K ^o   Uhlig, T ^p   Zavada, J ^q   Zhang, W ^b   Tubach, F ^f,s,t,u   Bardin, T ^a   more..

^a CENTRE VIGGO PETERSEN   (France)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^d V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f BICHAT HOSPITAL   (France)

^g Patient from Nottingham   (France)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ KEELE UNIVERSITY   (United Kingdom)

^j UNIVERSITY OF EDINBURGH   (United Kingdom)

^k HOSPITAL DE CRUCES   (Spain)

^l Rheumatology Unit   (Portugal)

^m UNIVERSITY OF PADOVA   (Italy)

ⁿ UNIVERSITY OF LAUSANNE   (Switzerland)

^o DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^p DIAKONHJEMMET HOSPITAL   (Norway)

^q CHARLES UNIVERSITY   (Czech Republic)

^r HÔPITAL LARIBOISIÈRE   (France)

^s UNIVERSITÉ PARIS DESCARTES   (France)

^t ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^u Institut National de la Santé et de la Recherche Médicale   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENZBROMARONE; CANAKINUMAB; COLCHICINE; CORTICOSTEROID; FEBUXOSTAT; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; PROBENECID; PROTON PUMP INHIBITOR; RILONACEPT; STEROID; URIC ACID; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR; ANTIGOUT AGENT; INTERLEUKIN 1;

DELPHI STUDY; DISEASE EXACERBATION; DRUG MEGADOSE; DRUG SUBSTITUTION; EUROPE; EVIDENCE BASED PRACTICE; GOUT; HUMAN; LOW DRUG DOSE; ORGANIZATION; PATIENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; RADIOLOGIST; REVIEW; RHEUMATOLOGIST; SYSTEMATIC REVIEW; URIC ACID BLOOD LEVEL; ANTAGONISTS AND INHIBITORS; BLOOD; DIRECTIVE COUNSELING; EVIDENCE BASED MEDICINE; LIFESTYLE; PATIENT EDUCATION; RECURRENT DISEASE;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DELPHI TECHNIQUE; DIRECTIVE COUNSELING; EVIDENCE-BASED MEDICINE; GOUT; GOUT SUPPRESSANTS; HUMANS; INTERLEUKIN-1; LIFE STYLE; PATIENT EDUCATION AS TOPIC; SYMPTOM FLARE UP; URIC ACID;

EID: 84979561898     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209707     Document Type: Review

References (192)

1. Bardin T, Bouée S, Clerson P, et al. Prevalence of gout in the Adult Population of France. Arthritis Care Res (Hoboken) 2016;68:261-6.
2. Trifirò G, Morabito P, Cavagna L, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: A nationwide population-based study. Ann Rheum Dis 2013;72:694-700.
3. Kuo CF, Grainge MJ, Mallen C, et al. Rising burden of gout in the UK but continuing suboptimal management: A nationwide population study. Ann Rheum Dis 2015;74:661-7.
4. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther 2010;12:223.
5. Kuo CF, Grainge MJ, Zhang W, et al. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 2015;11:649-62.
6. Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis 2012;71:1765-70.
7. Richette P, Clerson P, Périssin L, et al. Revisiting comorbidities in gout: A cluster analysis. Ann Rheum Dis 2015;74:142-7.
8. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
9. So A, Thorens B. Uric acid transport and disease. J Clin Invest 2010;120:1791-9.
10. Rock KL, Kataoka H, Lai JJ. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol 2013;9:13-23.
11. Diaz-Torné C, Perez-Herrero N, Perez-Ruiz F. New medications in development for the treatment of hyperuricemia of gout. Curr Opin Rheumatol 2015;27:164-9.
12. Edwards NL, So A. Emerging therapies for gout. Rheum Dis Clin North Am 2014;40:375-87.
13. Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum 2009;38:411-19.
14. Stamp LK, O'Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011;63:412-21.
15. Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol. Arthritis Rheum 2012;64:2529-36.
16. Hung SI, Chung WH, Liou LB, et al. HLA-B5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102:4134-9.
17. Perez-Ruiz F, Martínez-Indart L, Carmona L, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis 2014;73:177-82.
18. Dougados M, Betteridge N, Burmester GR, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004;63:1172-6.
19. van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 2015;74:8-13.
20. Colebatch-Bourn AN, Conaghan PG, Arden NK, et al. Raising the quality of rheumatology management recommendations: lessons from the EULAR process 10 years after provision of standard operating procedures. Rheumatology (Oxford) 2015;54:1392-6.
21. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008;67:960-6.
22. Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis 2007;66:1311-15.
23. Harrold LR, Mazor KM, Negron A, et al. Primary care providers' knowledge, beliefs and treatment practices for gout: results of a physician questionnaire. Rheumatology (Oxford) 2013;52:1623-9.
24. Kuo CF, Grainge MJ, Mallen C, et al. Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England. JAMA 2015;312:2684-6.
25. Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: A qualitative study. Ann Rheum Dis 2012;71:1490-5.
26. Reach G. Treatment adherence in patients with gout. Joint Bone Spine 2011;78:456-9.
27. Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009;11:R46.
28. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 2013;72:826-30.
29. Williams PT. Effects of diet, physical activity and performance, and body weight on incident gout in ostensibly healthy, vigorously active men. Am J Clin Nutr 2008;87:1480-7.
30. Dalbeth N, Chen P, White M, et al. Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: A prospective longitudinal study. Ann Rheum Dis 2014;73:797-802.
31. Zhu Y, Zhang Y, Choi HK. The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: The Multiple Risk Factor Intervention Trial. Rheumatology (Oxford) 2010;49:2391-9.
32. Richette P, Poitou C, Manivet P, et al. Weight loss, xanthine oxidase and serum urate levels: A prospective, longitudinal study of obese patients. Arthritis Care Res (Hoboken) 2016;68:1036-42.
33. Chen JH, Wen CP, Wu SB, et al. Attenuating the mortality risk of high serum uric acid: The role of physical activity underused. Ann Rheum Dis 2015;74:2034-42.
34. Roddy E, Choi HK. Epidemiology of gout. Rheum Dis Clin North Am 2014;40:155-75.
35. Bhole V, de Vera M, Rahman MM, et al. Epidemiology of gout in women: fifty-Two-year follow-up of a prospective cohort. Arthritis Rheum 2010;62:1069-76.
36. Zhang Y, Chen C, Choi H, et al. Purine-rich foods intake and recurrent gout attacks. Ann Rheum Dis 2012;71:1448-53.
37. Zhang Y, Woods R, Chaisson CE, et al. Alcohol consumption as a trigger of recurrent gout attacks. Am J Med 2006;119:800.e13-8.
38. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 2008;336:309-12.
39. Choi HK, Willett W, Curhan G. Fructose-rich beverages and risk of gout in women. JAMA 2010;304:2270-8.
40. Gao X, Qi L, Qiao N, et al. Intake of added sugar and sugar-sweetened drink and serum uric acid concentration in US men and women. Hypertension 2007;50:306-12.
41. Choi JW, Ford ES, Gao X, et al. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: The Third National Health and Nutrition Examination Survey. Arthritis Rheum 2008;59:109-16.
42. Choi HK, Curhan G. Coffee, tea, and caffeine consumption and serum uric acid level: The third national health and nutrition examination survey. Arthritis Rheum 2007;57:816-21.
43. Choi HK, Curhan G. Coffee consumption and risk of incident gout in women: The Nurses' Health Study. Am J Clin Nutr 2010;92:922-7.
44. Choi HK, Willett W, Curhan G. Coffee consumption and risk of incident gout in men: A prospective study. Arthritis Rheum 2007;56:2049-55.
45. Zhang Y, Neogi T, Chen C, et al. Cherry consumption and decreased risk of recurrent gout attacks. Arthritis Rheum 2012;64:4004-11.
46. Zgaga L, Theodoratou E, Kyle J, et al. The association of dietary intake of purine-rich vegetables, sugar-sweetened beverages and dairy with plasma urate, in a cross-sectional study. PLoS ONE 2012;7:e38123.
47. Dalbeth N, Wong S, Gamble GD, et al. Acute effect of milk on serum urate concentrations: A randomised controlled crossover trial. Ann Rheum Dis 2010;69:1677-82.
48. Dalbeth N, Ames R, Gamble GD, et al. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: A proof-of-concept randomised controlled trial. Ann Rheum Dis 2012;71:929-34.
49. Holland R, McGill NW. Comprehensive dietary education in treated gout patients does not further improve serum urate. Intern Med J 2015;45:189-94.
50. Moi JH, Sriranganathan MK, Falzon L, et al. Lifestyle interventions for the treatment of gout: A summary of 2 Cochrane systematic reviews. J Rheumatol Suppl 2014;92:26-32.
51. Krishnan E. Reduced glomerular function and prevalence of gout: NHANES 2009-10. PLoS ONE 2012;7:e50046.
52. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med 2011;125:679-687.e1.
53. Jalal DI, Chonchol M, Chen W, et al. Uric acid as a target of therapy in CKD. Am J Kidney Dis 2013;61:134-46.
54. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811-21.
55. Liu SC, Xia L, Zhang J, et al. Gout and risk of myocardial infarction: A systematic review and meta-Analysis of cohort studies. PLoS ONE 2015;10:e0134088.
56. Clarson LE, Hider SL, Belcher J, et al. Increased risk of vascular disease associated with gout: A retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis 2015;74:642-7.
57. Krishnan E, Baker JF, Furst DE, et al. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006;54:2688-96.
58. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894-900.
59. De Vera MA, Rahman MM, Bhole V, et al. Independent impact of gout on the risk of acute myocardial infarction among elderly women: A population-based study. Ann Rheum Dis 2010;69:1162-4.
60. Baker JF, Schumacher HR, Krishnan E. Serum uric acid level and risk for peripheral arterial disease: Analysis of data from the multiple risk factor intervention trial. Angiology 2007;58:450-7.
61. Krishnan E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open 2012;2:e000282.
62. Seminog OO, Goldacre MJ. Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies. Rheumatology (Oxford) 2013;52:2251-9.
63. Krishnan E, Akhras KS, Sharma H, et al. Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout. QJM 2013;106:721-9.
64. Keenan RT, O'Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011;124: 155-63.
65. Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010;62:1060-8.
66. van Durme CM, Wechalekar MD, Buchbinder R, et al. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev 2014;(9): CD010120.
67. Li T, Chen SL, Dai Q, et al. Etoricoxib versus indomethacin in the treatment of Chinese patients with acute gouty arthritis: A randomized double-blind trial. Chin Med J 2013;126:1867-71.
68. Schumacher HR, Berger MF, Li-Yu J, et al. Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: A randomized controlled trial. J Rheumatol 2012;39:1859-66.
69. Willburger RE, Mysler E, Derbot J, et al. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatology (Oxford) 2007;46:1126-32.
70. Rainer TH, Cheng CH, Janssens HJ, et al. Oral prednisolone in the treatment of acute gout: A pragmatic, multicenter, double-blind, randomized trial. Ann Intern Med 2016;164:464-71.
71. Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: A double-blind, randomised equivalence trial. Lancet 2008;371:1854-60.
72. Man CY, Cheung IT, Cameron PA, et al. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute gout-like arthritis: A double-blind, randomized, controlled trial. Ann Emerg Med 2007;49:670-7.
73. Terkeltaub RA, Furst DE, Digiacinto JL, et al. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum 2011;63:2226-37.
74. Richette P, Bardin T. Colchicine for the treatment of gout. Expert Opin Pharmacother 2010;11:2933-8.
75. Wason S, Mount D, Faulkner R. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clin Drug Investig 2014;34:845-55.
76. Fernández C, Noguera R, González JA, et al. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 1999;26:2285-6.
77. Wechalekar MD, Vinik O, Schlesinger N, et al. Intra-Articular glucocorticoids for acute gout. Cochrane Database Syst Rev 2013;(4):CD009920.
78. Martinon F, Pétrilli V, Mayor A, et al. Gout-Associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41.
79. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012;71:1839-48.
80. So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;9:R28.
81. Chen K, Fields T, Mancuso CA, et al. Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum 2010;40:210-14.
82. Ottaviani S, Moltó A, Ea HK, et al. Efficacy of anakinra in gouty arthritis: A retrospective study of 40 cases. Arthritis Res Ther 2013;15:R123.
83. Ghosh P, Cho M, Rawat G, et al. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res (Hoboken) 2013;65:1381-4.
84. Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009;68:1613-17.
85. Terkeltaub RA, Schumacher HR, Carter JD, et al. Rilonacept in the treatment of acute gouty arthritis: A randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther 2013;15:R25.
86. Schlesinger N. Canakinumab in gout. Expert Opin Biol Ther 2012;12:1265-75.
87. Becker MA, MacDonald PA, Hunt BJ, et al. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids 2008;27:585-91.
88. Wortmann RL, Macdonald PA, Hunt B, et al. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: Analysis of data from three phase III trials. Clin Ther 2010;32:2386-97.
89. Finkelstein Y, Aks SE, Hutson JR, et al. Colchicine poisoning: The dark side of an ancient drug. Clin Toxicol (Phila) 2010;48:407-14.
90. Nidorf SM, Eikelboom JW, Budgeon CA, et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013;61:404-10.
91. Deftereos S, Giannopoulos G, Raisakis K, et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J Am Coll Cardiol 2013;61:1679-85.
92. Schlesinger N, Mysler E, Lin HY, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 2011;70:1264-71.
93. Schumacher HR Jr, Sundy JS, Terkeltaub R, et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2012;64:876-84.
94. Mitha E, Schumacher HR, Fouche L, et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology (Oxford) 2013;52:1285-92.
95. Schumacher HR Jr, Evans RR, Saag KG, et al. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) 2012;64:1462-70.
96. Sundy JS, Schumacher HR, Kivitz A, et al. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. J Rheumatol 2014;41:1703-11.
97. Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540-8.
98. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.
99. Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: Two randomized controlled trials. JAMA 2011;306:711-20.
100. Baraf HS, Becker MA, Gutierrez-Urena SR, et al. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther 2013;15:R137.
101. Strand V, Khanna D, Singh JA, et al. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. J Rheumatol 2012;39:1450-7.
102. Richette P. Debulking the urate load to feel better. J Rheumatol 2012;39:1311-13.
103. Scire CA, Manara M, Cimmino MA, et al. Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR). Arthritis Res Ther 2013;15:R101.
104. Becker MA, Schumacher HR, Benjamin KL, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol 2009;36:1041-8.
105. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis 2008;67:1310-16.
106. Chandratre P, Roddy E, Clarson L, et al. Health-related quality of life in gout: A systematic review. Rheumatology (Oxford) 2013;52:2031-40.
107. Stack AG, Hanley A, Casserly LF, et al. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM 2013;106:647-58.
108. Bhole V, Krishnan E. Gout and the heart. Rheum Dis Clin North Am 2014;40:125-43.
109. Richette P, Perez-Ruiz F. Serum uric acid and metabolic risk. Curr Med Res Opin 2013;29(Suppl 3):9-15.
110. Krishnan E, Svendsen K, Neaton JD, et al. Long-Term cardiovascular mortality among middle-Aged men with gout. Arch Intern Med 2008;168: 1104-10.
111. Higgins P, Dawson J, Lees KR, et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: A systematic review and meta-Analysis. Cardiovasc Ther 2012;30:217-26.
112. Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: A systematic review and meta-Analysis. J Clin Hypertens (Greenwich) 2013;15:435-42.
113. Goicoechea M, Garcia de Vinuesa S, Verdalles U, et al. Allopurinol and progression of CKD and cardiovascular events: long-Term follow-up of a randomized clinical trial. Am J Kidney Dis 2015;65:543-9.
114. Bose B, Badve SV, Hiremath SS, et al. Effects of uric acid-lowering therapy on renal outcomes: A systematic review and meta-Analysis. Nephrol Dial Transplant 2014;29:406-13.
115. Kanji T, Gandhi M, Clase CM, et al. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-Analysis. BMC Nephrol 2015;16:58.
116. Sircar D, Chatterjee S, Waikhom R, et al. Efficacy of Febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: A 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 2015;66:945-50.
117. Noman A, Ang DS, Ogston S, et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: A randomised, placebo controlled crossover trial. Lancet 2010;375:2161-7.
118. Kelkar A, Kuo A, Frishman WH. Allopurinol as a cardiovascular drug. Cardiol Rev 2011;19:265-71.
119. Thanassoulis G, Brophy JM, Richard H, et al. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med 2010;170:1358-64.
120. Givertz MM, Anstrom KJ, Redfield MM, et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: The xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study. Circulation 2015;131:1763-71.
121. Grimaldi-Bensouda L, Alpérovitch A, Aubrun E, et al. Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis 2015;74:836-42.
122. de Abajo FJ, Gil MJ, Rodríguez A, et al. Allopurinol use and risk of non-fatal acute myocardial infarction. Heart 2015;101:679-85.
123. Kok VC, Horng JT, Chang WS, et al. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: A population-based matched-cohort study. PLoS ONE 2014;9:e99102.
124. Saag KG, Whelton A, Becker MA, et al. Impact of febuxostat on renal function in gout subjects with moderate-To-severe renal impairment. Arthritis Rheumatol 2016. [Epub ahead of print 19 Feb 2016]. doi:10.1002/art.39654
125. Wu EQ, Patel PA, Mody RR, et al. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol 2009;36:1032-40.
126. Abhishek A, Valdes AM, Zhang W, et al. Serum uric acid & disease duration associate with frequent gout attacks but are poor at identifying such patients: A case control study. Arthritis Care Res (Hoboken) 2016. [Epub ahead of print 11 Feb 2016]. doi:10.1002/acr.22855
127. Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: A systematic review of the literature. Curr Opin Rheumatol 2011;23:192-202.
128. Rothenbacher D, Primatesta P, Ferreira A, et al. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford) 2011;50:973-81.
129. Yamanaka H. Gout and hyperuricemia in young people. Curr Opin Rheumatol 2011;23:156-60.
130. Taylor TH, Mecchella JN, Larson RJ, et al. Initiation of allopurinol at first medical contact for acute attacks of gout: A randomized clinical trial. Am J Med 2012;125:1126-1134.e7.
131. Hill EM, Sky K, Sit M, et al. Does starting allopurinol prolong acute treated gout? A randomized clinical trial. J Clin Rheumatol 2015;21:120-5.
132. Bardin T. Hyperuricemia starts at 360 micromoles (6 mg/dL). Joint Bone Spine 2015;82:141-3.
133. Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007;66:1056-8.
134. Perez-Ruiz F, Lioté F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007;57:1324-8.
135. Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-60.
136. Chamorro A, Amaro S, Castellanos M, et al. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): A randomised, double-blind phase 2b/3 trial. Lancet Neurol 2014;13:453-60.
137. Peng F, Zhang B, Zhong X, et al. Serum uric acid levels of patients with multiple sclerosis and other neurological diseases. Mult Scler 2008;14:188-96.
138. Schretlen DJ, Inscore AB, Vannorsdall TD, et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology 2007;69:1418-23.
139. Chen H, Mosley TH, Alonso A, et al. Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2009;169:1064-9.
140. Weisskopf MG, O'Reilly E, Chen H, et al. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 2007;166:561-7.
141. Kim TS, Pae CU, Yoon SJ, et al. Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2006;21:344-8.
142. Abraham A, Drory VE. Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: A meta-Analysis. J Neurol 2014;261:1133-8.
143. Zandman-Goddard G, Amital H, Shamrayevsky N, et al. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel. Rheumatology (Oxford) 2013;52:1126-31.
144. Solomon DH, Avorn J, Levin R, et al. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis 2008;67:609-13.
145. Perez-Ruiz F, Herrero-Beites AM, Carmona L. A two-stage approach to the treatment of hyperuricemia in gout: The "dirty dish" hypothesis. Arthritis Rheum 2011;63:4002-6.
146. Meltzer M, Pizzi LT, Jutkowitz E. Payer decision-making with limited comparative and cost effectiveness data: The case of new pharmacological treatments for gout. Evid Based Med 2012;17:105-8.
147. Jutkowitz E, Choi HK, Pizzi LT, et al. Cost-effectiveness of allopurinol and febuxostat for the management of gout. Ann Intern Med 2014;161:617-26.
148. Reinders MK, van Roon EN, Jansen TL, et al. Efficacy and tolerability of urate-lowering drugs in gout: A randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 2009;68:51-6.
149. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: The CONFIRMS trial. Arthritis Res Ther 2010;12:R63.
150. Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis 2009;68:892-7.
151. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005;52:916-23.
152. Abeles AM. Febuxostat hypersensitivity. J Rheumatol 2012;39:659.
153. Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol 2011;38:1957-9.
154. Bardin T, Chalès G, Pascart T, et al. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine 2016;83:314-17.
155. Kydd AS, Seth R, Buchbinder R, et al. Uricosuric medications for chronic gout. Cochrane Database Syst Rev 2014;(11):CD010457.
156. Pui K, Gow PJ, Dalbeth N. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. J Rheumatol 2013;40:872-6.
157. Reinders MK, van Roon EN, Houtman PM, et al. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-Treated gout patients. Clin Rheumatol 2007;26:1459-65.
158. Stocker SL, Graham GG, McLachlan AJ, et al. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol 2011;38:904-10.
159. Ko TM, Tsai CY, Chen SY, et al. Use of HLA-B58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ 2015;351:h4848.
160. Perez-Ruiz F, Sundy JS, Miner JN, et al. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis 2016;75:1074-80.
161. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008;58:25-32.
162. Kim SC, Newcomb C, Margolis D, et al. Severe cutaneous reactions requiring hospitalization in allopurinol initiators: A population-based cohort study. Arthritis Care Res (Hoboken) 2013;65:578-84.
163. Ramasamy SN, Korb-Wells CS, Kannangara DR, et al. Allopurinol hypersensitivity: A systematic review of all published cases, 1950-2012. Drug Saf 2013;36:953-80.
164. Chung WH, Chang WC, Stocker SL, et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: The impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis 2015;74:2157-64.
165. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep 2009;11:135-40.
166. Stocker SL, McLachlan AJ, Savic RM, et al. The pharmacokinetics of oxypurinol in people with gout. Br J Clin Pharmacol 2012;74:477-89.
167. Yun J, Mattsson J, Schnyder K, et al. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Clin Exp Allergy 2013;43:1246-55.
168. Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006;33:1646-50.
169. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
170. Hira D, Chisaki Y, Noda S, et al. Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. Pharmacology 2015;96:90-8.
171. Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, et al. Treatment of chronic gout in patients with renal function impairment: An open, randomized, actively controlled study. J Clin Rheumatol 1999;5:49-55.
172. Fujimori S, Ooyama K, Ooyama H, et al. Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease. Nucleosides Nucleotides Nucleic Acids 2011;30:1035-8.
173. Sundy JS, Becker MA, Baraf HS, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase ( polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum 2008;58:2882-91.
174. Lipsky PE, Calabrese LH, Kavanaugh A, et al. Pegloticase immunogenicity: The relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther 2014;16:R60.
175. Choi HK, Soriano LC, Zhang Y, et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 2012;344:d8190.
176. Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-Analysis of randomized placebo-controlled trials. Pharmacol Res 2015;102:63-70.
177. Ansquer JC, Dalton RN, Caussé E, et al. Effect of fenofibrate on kidney function: A 6-week randomized crossover trial in healthy people. Am J Kidney Dis 2008;51:904-13.
178. Ogata N, Fujimori S, Oka Y, et al. Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. Nucleosides Nucleotides Nucleic Acids 2010;29:321-4.
179. Takagi H, Umemoto T. Atorvastatin therapy reduces serum uric acid levels: A meta-Analysis of randomized controlled trials. Int J Cardiol 2012;157:255-7.
180. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011;63:3136-41.
181. Crittenden DB, Pillinger MH. New therapies for gout. Annu Rev Med 2013;64:325-37.
182. Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol 2014;26:186-91.
183. Dalbeth N, House ME, Aati O, et al. Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: A dual energy CT study. Ann Rheum Dis 2015;74:908-11.
184. Dalbeth N, Stamp L. Hyperuricaemia and gout: Time for a new staging system? Ann Rheum Dis 2014;73:1598-600.
185. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64:1431-46.
186. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012;64:1447-61.
187. Saito Y, Stamp LK, Caudle KE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther 2015; 99:36-7.
188. Yun J, Marcaida MJ, Eriksson KK, et al. Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B58:01. J Immunol 2014;192:2984-93.
189. Lin CH, Chen JK, Ko TM, et al. Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B58:01-restricted activation of drug-specific T cells and molecular interaction. J Allergy Clin Immunol 2015;135: 1063-5.e5.
190. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008;18:99-107.
191. Saokaew S, Tassaneeyakul W, Maenthaisong R, et al. Cost-effectiveness analysis of HLA-B5801 testing in preventing allopurinol-induced SJS/TEN in Thai population. PLoS ONE 2014;9:e94294.
192. Park DJ, Kang JH, Lee JW, et al. Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea. Arthritis Care Res (Hoboken) 2015;67:280-7.